Other OTC - Delayed Quote USD

Roche Holding AG (RHHBY)

30.02

-0.52

(-1.70%)

At close: April 25 at 3:59 PM EDT

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Zacks yesterday

ROG.SW

BAYRY
+0.14%
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales

Roche confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter sales slipped by 6% on the loss on COVID-19-related revenue. Quarterly sales fell to 14.4 billion Swiss francs ($15.80 billion), the family-controlled drugmaker said in a statement on Wednesday, hurt also by a strong Swiss franc that weighed on overseas revenue but in line with analysts expectations. Roche, which does not disclose quarterly earnings, said the rest of the year would no longer be burdened by year-earlier comparisons that were inflated by COVID-related sales.

Reuters yesterday

ROG.SW
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Division base business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, su

GlobeNewswire yesterday

RHHBF

RHHBY
-1.70%
RHHVF
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Zacks 6 days ago

ROG.SW
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.

Zacks 6 days ago

ABBV

LLY
-1.00%
ROG.SW
Roche wins FDA OK for Alecensa in early lung cancer

Alecensa is the first targeted drug available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.

BioPharma Dive 6 days ago

ROG.SW
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF

GlobeNewswire 6 days ago

RHHBF

RHHBY
-1.70%
RHHVF
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi

Business Wire 7 days ago

RHHBF

RHHBY
-1.70%
RHHVF
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

SOUTH SAN FRANCISCO, Calif., April 17, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the Phase III OCARINA II study (S31.006) of Ocrevus® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigatio

Business Wire 8 days ago

RHHBF

RHHBY
-1.70%
RHHVF
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. ap

GlobeNewswire 8 days ago

RHHBF

RHHBY
-1.70%
RHHVF
Adaptimmune (ADAP) Down on End of Collaboration With Roche

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Zacks 10 days ago

ADAP

ROG.SW
Roche reports survival data for new dual-acting lymphoma drug

The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

BioPharma Dive 10 days ago

ROG.SW

ABBV

GMAB.CO
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.

Zacks 10 days ago

ROG.SW

ALXO

NRIX
Roche to distribute Prenosis’ AI sepsis detection tool in US

Roche will make the tool available as part of its Navify Algorithm Suite, a collection of medical algorithms the company has validated.

MedTech Dive 10 days ago

ROG.SW
$Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study$
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

SOUTH SAN FRANCISCO, Calif., April 15, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, lived longer when treated with Columvi® (glofitamab-gxbm) in combination wi

Business Wire 10 days ago

RHHBF

RHHBY
-1.70%
RHHVF
$[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study$
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meeting Basel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or re

GlobeNewswire 10 days ago

RHHBF

RHHBY
-1.70%
RHHVF
Roche scores FDA breakthrough status for Alzheimer’s blood test

The plasma assay is intended to aid in finding amyloid pathology, a biomarker of Alzheimer’s disease.

MedTech Dive 13 days ago

ROG.SW
Roche, Adaptimmune part ways on cell therapy research

The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

BioPharma Dive 13 days ago

ADAP

ROG.SW
Why Roche Holdings Stock Popped Today

Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.

Motley Fool 14 days ago

ROG.SW
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

Zacks 14 days ago

ALXO

ROG.SW

NRIX

Performance Overview

Return	RHHBY	MSCI WORLD
YTD	-13.62%	+4.39%
1-Year	-21.07%	+17.03%
3-Year	-21.33%	+12.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (RHHBY)

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

Roche wins FDA OK for Alecensa in early lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Roche reports survival data for new dual-acting lymphoma drug

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Roche to distribute Prenosis’ AI sepsis detection tool in US

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Roche scores FDA breakthrough status for Alzheimer’s blood test

Roche, Adaptimmune part ways on cell therapy research

Why Roche Holdings Stock Popped Today

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

Performance Overview